BioElectronics Reports Sales Growth and Strategic Progress in Chairman’s Update

BioElectronics Corporation (OTC: BIEL) released an update from Chairman Richard Staelin, PhD, highlighting sales growth, cost control achievements, and strategic milestones. The company, a developer of medical technology products, reported a small profit for the calendar year 2025, driven by disciplined cost control measures including office relocation and staff reductions. These efforts align with the company’s focus on expanding revenues and markets while maintaining financial discipline.

The company has initiated targeted advertising campaigns directed at medical professionals to increase awareness of RecoveryRx, its non-opioid pain management device. These campaigns target surgeons, pain specialists, rehabilitation providers, and chiropractors. Additionally, consumer-focused social media advertising campaigns are targeting Generation X consumers seeking drug-free solutions for chronic musculoskeletal pain. The net result of these initiatives is an increase in monthly sales in both over-the-counter and professional markets.

In a significant operational milestone, BioElectronics announced that its strategic distribution and licensing relationship with Electrome Corporation has moved forward. Initial conditions of the supply agreement have been satisfied, and Electrome has placed its initial purchase order. Manufacturing is underway, and Electrome is planning a commercial launch of BioElectronics’ pulsed shortwave therapy products through its platform. This partnership provides another pathway to increase consumer awareness and access to the company’s FDA-cleared, drug-free pain therapy products.

The company continues its outreach to physician-owned ambulatory surgical centers and orthopedic practices to identify a clinical trial partner for RecoveryRx. The objective is to participate in a postoperative clinical study that may support future qualification for reimbursement under the federal NO PAIN Act initiative. Staelin emphasized that this represents a meaningful long-term opportunity for broader adoption of non-opioid pain management technologies in surgical settings.

Internationally, BioElectronics is working with legal counsel in Singapore and funders in China regarding arbitration proceedings involving a former distributor that allegedly breached contractual obligations. While arbitration processes are lengthy, the company remains committed to protecting its intellectual property, contractual rights, and shareholder interests.

Despite challenges faced by emerging medical technology companies, Staelin expressed encouragement by the growing interest in non-drug pain management solutions. He believes BioElectronics is well positioned within the evolving electroceutical and non-opioid pain management markets. The company intends to continue advancing initiatives that support sustainable growth, including clinical market development, direct professional outreach, consumer education, and international opportunities.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is BioElectronics Reports Sales Growth and Strategic Progress in Chairman’s Update.

The post BioElectronics Reports Sales Growth and Strategic Progress in Chairman’s Update appeared first on citybuzz.